Experience

• Mr. Barrett has represented:

  • Adimab in its antibody platform licensing agreements with GSK (2013), Biogen Idec (2013), Novo Nordisk (2013) and Merck (2015)
  • Agios Pharmaceuticals in its IDHIFA® royalty and milestone sale transaction with Royalty Pharma (2020)
  • Agios Pharmaceuticals in its Chinese territory collaboration and license agreement for Ivosidenib with CStone Pharmaceuticals (2018)
  • Agios Pharmaceuticals in its metabolic immuno-oncology collaborations with Celgene (2010 and 2016)
  • Apellis Pharmaceuticals in its complement-driven disease collaboration with Beam Therapeutics (2021)
  • Apellis Pharmaceuticals in its systemic pegcetacoplan collaboration with Sobi (2020)
  • Apellis Pharmaceuticals in its pegcetacoplan hematologic indication collaboration with SFJ Pharmaceuticals (2019)
  • Beam Therapeutics in its multi-target research collaboration for base editing programs for rare diseases with Pfizer (2022)
  • Carisma Therapeutics in its strategic collaboration agreement for in vivo engineered chimeric antigen receptor monocyte (CAR-M) cancer therapeutics with Moderna (2022)
  • Cybrexa Therapeutics in its collaboration and program acquisition option agreements for Cybrexa’s CBX-12 peptide-drug conjugate with Exelixis (2022)
  • D.E. Shaw Research in its exclusive license agreement for DES-7114 with Lilly (2022)
  • Editas Medicine in its amended collaboration for gene-edited autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases with Celgene (2019)
  • Editas Medicine in its gene editing and cell therapy platform collaboration with BlueRock Therapeutics (2019)
  • Editas Medicine in its licensing agreement for base editing technology with Beam Therapeutics (2018)
  • Editas Medicine in its strategic alliance and option agreement with Allergan (2017)
  • Editas Medicine in its licensing of CRISPR technologies from the Broad Institute, MIT, Harvard and other academic institutions (2016)
  • Epizyme in its Tazverik royalty sale transaction with Royalty Pharma (2019)
  • Epizyme in its combination clinical trial collaboration with Genentech (2016)
  • ImaginAb in its divestiture of its radiopharmaceutical therapy business to Telix Pharmaceuticals (2025)
  • Incyte in its worldwide collaboration and licensing agreement for axatilimab with Syndax Pharmaceuticals (2021)
  • Iveric Bio in its >$1 billion ex-US licensing and commercialization agreement for FOVISTA^™ with Novartis (2014)
  • Lexicon in its worldwide collaboration and licensing agreement for sotagliflozin with Sanofi (2015)
  • Lexicon in its ex-US and Japan licensing agreement for telotristat etiprate with Ipsen (2014)
  • MacroGenics in its anti-PD-1 monoclonal antibody collaboration with Incyte (2017)
  • Mediar Therapeutics in its worldwide licensing agreement for Mediar’s MTX-463 antibody with Eli Lilly (2025)
  • Mersana Therapeutics in its worldwide collaboration, option and license agreement for XMT-2056 with GlaxoSmithKline (2022)
  • Novo Nordisk in its cardiometabolic and rare disease collaboration with Flagship Pioneering (2022)
  • Novo Nordisk in its RNAi therapy collaboration for liver-related cardio-metabolic diseases with Dicerna Pharmaceuticals (2019)
  • Ocular Therapeutix in its Asian territory collaboration and license agreement for DEXTENZA and OTX-TIC with AffaMed (2020)
  • PTC Therapeutics in its Risdiplam royalty monetization agreement with Royalty Pharma (2020)
  • Repare Therapeutics in its worldwide license and collaboration agreement for Camonsertib (RP-3500) with Roche (2022)
  • Repare Therapeutics in its synthetic lethal oncology target discovery collaboration with Bristol-Myers Squibb (2020)
  • Ribometrix in its RNA-targeted small molecule therapeutic discovery and development collaboration with Genentech (2020)
  • Ribometrix in its RNA-targeted small molecule therapeutic discovery and development collaboration with Vertex Pharmaceuticals (2019)
  • Ribon Therapeutics in its Asian territory collaboration and license agreement for RBN-2397 with Ono Pharmaceutical Co., Ltd. (2021)
  • Spark Therapeutics in its ex-US licensing and commercialization agreement for LUXTURNA^™ with Novartis (2018)
  • Vividion Therapeutics in its small molecule ubiquitin proteome collaboration with Celgene (2018)
  • vTv Therapeutics in its licensing agreements with Reneo Pharmaceuticals (2017), Newsoara Biopharma Co. (2018) and Anteris (2020)